Literature DB >> 33448429

Cross-sectional study of histopathology and piscine orthoreovirus during a marine production cycle of farmed Atlantic salmon (Salmo salar L.) in British Columbia, Canada.

Gary D Marty1, Julie Bidulka1, Tomy Joseph1.   

Abstract

Two cohorts of farmed Atlantic salmon, Salmo salar L., in British Columbia, Canada, were sampled for histopathology (nine organs) and piscine orthoreovirus (PRV-1) PCR after seawater entry at 2, 4, 6, 8, 10, 13, 16 and 19 months (20 fish per cohort per date). One cohort-from a PRV+ hatchery-remained PRV+ throughout the study (sample prevalence 80%-100%). In an adjacent pen, the other cohort-from a PRV- hatchery-was 0% PRV+ at 78 days, 30% PRV+ at 128 days and ≥95% PRV+ thereafter. Among sample cohorts that were ≥80% PRV+, median Ct values were nominally less among fish sourced from the PRV- hatchery (28.7-33.3) than the PRV+ hatchery (30.8-35.2). No microscopic lesions were associated with PRV Ct value (minimum = 25.6). About 3% of fish in both cohorts had moderate inflammatory heart lesions; among these fish, only one had skeletal muscle inflammation (mild), and PRV Ct values were similar to unaffected cohorts sampled the same day. Also, among 16 moribund or freshly dead fish sampled opportunistically during the study, 14 were PRV+, and none had significant inflammatory heart lesions. These data support the hypothesis that British Columbia PRV-1 does not contribute to mortality.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  cross‐sectional study; farmed Atlantic salmon; histopathology; piscine orthoreovirus

Mesh:

Year:  2020        PMID: 33448429     DOI: 10.1111/jfd.13210

Source DB:  PubMed          Journal:  J Fish Dis        ISSN: 0140-7775            Impact factor:   2.767


  1 in total

1.  Heart inflammation and piscine orthoreovirus genotype-1 in Pacific Canada Atlantic salmon net-pen farms: 2016-2019.

Authors:  Mark P Polinski; Lynden A Gross; Gary D Marty; Kyle A Garver
Journal:  BMC Vet Res       Date:  2022-08-10       Impact factor: 2.792

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.